WuXi Biologics Shines at The Asset Corporate Sustainability Leadership Awards 2026 with Jade Award
On October 21, 2026, WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), celebrated a remarkable achievement at The Asset Corporate Sustainability Leadership Awards by receiving the prestigious Jade Award, alongside the title of Best in Transition (Hong Kong). This recognition distinguishes WuXi Biologics as the only pharmaceutical company among the recipients of this year’s Jade Award.
The Jade Award represents the highest level of honor within the program and is awarded to organizations that successfully incorporate sustainability into their overall strategy and operations. It recognizes superior leadership in key areas such as governance, resilience, innovation, and long-term value creation. WuXi Biologics views this accolade as validation from both investors and industry peers regarding its ongoing commitment to enhancing environmental, social, and governance (ESG) principles.
Dr. Chris Chen, the CEO of WuXi Biologics and Chairman of its ESG Committee, expressed his gratitude, stating, "We are honored to receive this recognition from The Asset. Sustainability is integral to our mission of enabling our clients and benefiting patients. WuXi Biologics will continue to strengthen ESG governance and advance its Green CRDMO solutions." The company aims to foster the pharmaceutical industry’s transition to greener practices while creating long-term value through responsible operations and innovation.
At the heart of WuXi Biologics' success is a robust four-tier governance structure led by its ESG Committee. This integrated management framework encompasses strategy formulation, resource allocation, operational execution, and overall business governance, ensuring that sustainability principles are embedded in both strategic decision-making and daily operations. Its outstanding performance in ESG governance has earned the company multiple global accolades, including an MSCI AAA rating and recognition as an Industry and Regional ESG Leader from Morningstar Sustainalytics.
In addition to the Jade Award, WuXi Biologics also secured the Best in Transition award, which highlights its progress in sustainable and digital transformation. The organization employs comprehensive Green CRDMO solutions that integrate sustainable practices throughout the lifecycle of biologics research, development, and manufacturing. By prioritizing resource efficiency and environmental stewardship, WuXi Biologics commits to continual improvement through green technology, enhanced energy efficiency, and collaboration across the value chain.
Furthermore, by intertwining digitization with sustainability through a Smart ESG management platform, WuXi Biologics enhances data integration and monitoring capabilities, ultimately improving efficiency and decision-making related to ESG initiatives.
Established as a leader within the CRDMO market, WuXi Biologics offers comprehensive end-to-end solutions that help partners navigate the journey from discovery and development to manufacturing of biologics. With a global workforce exceeding 14,000 employees, the company operates across various locations, including China, the United States, and several European countries. Its mission underscores a commitment to sustainable business growth and the empowerment of patients worldwide through innovative healthcare solutions.
WuXi Biologics' ongoing dedication to sustainability reflects its core belief that social and environmental responsibility is vital to success in today’s market. Continuous technological advancements enable them to provide advanced Green CRDMO solutions while promoting best practices in environmental, social, and governance criteria. Collaborating with stakeholders across the industry, the company emphasizes the collective importance of generating positive social and environmental impacts, reinforcing responsible practices across the entire biopharmaceutical value chain.
For more information about WuXi Biologics and its commitment to sustainability and innovation, visit www.wuxibiologics.com.
The Jade Award represents the highest level of honor within the program and is awarded to organizations that successfully incorporate sustainability into their overall strategy and operations. It recognizes superior leadership in key areas such as governance, resilience, innovation, and long-term value creation. WuXi Biologics views this accolade as validation from both investors and industry peers regarding its ongoing commitment to enhancing environmental, social, and governance (ESG) principles.
Dr. Chris Chen, the CEO of WuXi Biologics and Chairman of its ESG Committee, expressed his gratitude, stating, "We are honored to receive this recognition from The Asset. Sustainability is integral to our mission of enabling our clients and benefiting patients. WuXi Biologics will continue to strengthen ESG governance and advance its Green CRDMO solutions." The company aims to foster the pharmaceutical industry’s transition to greener practices while creating long-term value through responsible operations and innovation.
At the heart of WuXi Biologics' success is a robust four-tier governance structure led by its ESG Committee. This integrated management framework encompasses strategy formulation, resource allocation, operational execution, and overall business governance, ensuring that sustainability principles are embedded in both strategic decision-making and daily operations. Its outstanding performance in ESG governance has earned the company multiple global accolades, including an MSCI AAA rating and recognition as an Industry and Regional ESG Leader from Morningstar Sustainalytics.
In addition to the Jade Award, WuXi Biologics also secured the Best in Transition award, which highlights its progress in sustainable and digital transformation. The organization employs comprehensive Green CRDMO solutions that integrate sustainable practices throughout the lifecycle of biologics research, development, and manufacturing. By prioritizing resource efficiency and environmental stewardship, WuXi Biologics commits to continual improvement through green technology, enhanced energy efficiency, and collaboration across the value chain.
Furthermore, by intertwining digitization with sustainability through a Smart ESG management platform, WuXi Biologics enhances data integration and monitoring capabilities, ultimately improving efficiency and decision-making related to ESG initiatives.
Established as a leader within the CRDMO market, WuXi Biologics offers comprehensive end-to-end solutions that help partners navigate the journey from discovery and development to manufacturing of biologics. With a global workforce exceeding 14,000 employees, the company operates across various locations, including China, the United States, and several European countries. Its mission underscores a commitment to sustainable business growth and the empowerment of patients worldwide through innovative healthcare solutions.
WuXi Biologics' ongoing dedication to sustainability reflects its core belief that social and environmental responsibility is vital to success in today’s market. Continuous technological advancements enable them to provide advanced Green CRDMO solutions while promoting best practices in environmental, social, and governance criteria. Collaborating with stakeholders across the industry, the company emphasizes the collective importance of generating positive social and environmental impacts, reinforcing responsible practices across the entire biopharmaceutical value chain.
For more information about WuXi Biologics and its commitment to sustainability and innovation, visit www.wuxibiologics.com.
Topics General Business）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.